Melanotan 1 (10mg)

Melanotan 1 Peptide and Erythropoietic Protoporphyria

Melanotan 1, a synthetic peptide closely resembling the endogenous α-MSH, has garnered significant attention in scientific exploration, particularly concerning its potential role in erythropoietic protoporphyria. This hereditary condition is characterized by an abnormal elevation of porphyrins, attributed to the deficiency of enzymes crucial for hemoglobin synthesis. The slight structural deviation of Melanotan 1 from the endogenous peptide hormone is speculated to contribute to its enhanced bioactivity, possibly fostering increased affinity for target cells and an extended half-life in comparison to α-MSH. Ongoing research aims to elucidate the peptide’s impact on mitigating the biochemical imbalances associated with erythropoietic protoporphyria.

Overview

Melanotan I, mirroring the function of endogenous α-MSH, is believed to engage with melanocortin receptors, potentially triggering the synthesis of eumelanin. In subjects with erythropoietic porphyria lacking the enzyme ferrochelatase, essential for heme production, excessive protoporphyrin accumulates, posing a risk of tissue damage upon UV exposure. Melanotan I’s interaction with melanocortin receptors is hypothesized to stimulate eumelanin production, providing a photoprotective shield against UV-induced reactive oxygen species. This mechanism may contribute to safeguarding tissues from oxidative damage and is associated with the observed increase in skin pigmentation following Melanotan I administration. Ongoing investigations seek to elucidate the peptide’s precise impact on these photoprotective pathways.

Exploration and Clinical Investigations

Therapeutic Exploration and Melanotan 1 Peptide Efficacy

Three clinical trials were initiated to investigate the potential impact of Melanotan on individuals with erythropoietic porphyria. Each trial employed a division of subjects into two groups, one administered with the peptide and the other with a placebo. The participants received either the peptide or the placebo every two months and underwent monitoring for a period of 180 days. Subjects recorded their direct sunlight exposure hours and reported any pain experienced during sunlight exposure. The results indicated that individuals receiving the peptide could reportedly spend more time in sunlight without pain (approximately 64 hours) compared to those presented with a placebo (approximately 40 hours).

Photobiological Interaction and Melanotan 1 Peptide Efficacy

This clinical investigation(7) aimed to elucidate the mechanism of action of the peptide when combined with UV-B light or sunlight. The study comprised three distinct phases, each serving as a clinical trial. In the initial study, four subjects received the peptide, and four subjects were given a placebo for 10 days. The second study involved 12 subjects receiving the peptide for 10 days, with seven subjects exposed to UV irradiation and five subjects exposed to UV radiation. The final study, conducted with eight subjects, half of whom received the peptide and the other half a placebo, involved exposing all subjects to sunlight on their backs for 3 to 5 days per week. Across all three trials, researchers reported consistent outcomes suggesting a positive correlation between peptide administration and melanin production, observed at both the cellular level and in the subjects’ varying degrees of tanning.
Melanotan 1 peptide is exclusively intended for scientific and laboratory investigations. Prior to placing an order, it is imperative to thoroughly review and comply with our specified Terms and Conditions.